drugset / Trial / NCT04784143

Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD

NCT04784143

Phase 2 Terminated 26 enrolled Resilient Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is effective in U.S. military veterans with at least moderate chronic PTSD. The main question it aims to answer is: Are two versus three MDMA-assisted therapy sessions in an outpatient treatment clinic more effective? Researchers will compare two MDMA-assisted therapy sessions to three MDMA-assisted therapy sessions. Participants will undergo three non-drug preparatory sessions prior to their first MDMA-assisted therapy session. Each MDMA-assisted therapy session will be followed by three non-drug integrative therapy sessions.

Timeline

Start
2021-11-08
Primary completion
2024-06-25
Completion
2024-06-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Midomafetamine Unknown 120 mg